2019台灣生技月 Bio Taiwan 生物科技大展

2019 台灣生技月 南港展覽館

同期會議

Academia Bio-Innotech Presentation

 



Taiwan possesses strong biotech talent and R&D base. As PhrMA posted in 2017, Taiwan ranked 3rd among 21 emerging countries for its biotech efforts, in particular in the fields of basic infrastructure, practical research and copyright protection.
 
For raising the value of the innovative research discoveries, the BioMed Commercialization Center (Drug Division, BMCC|Drug) was set up by Taiwan government with the mission to optimize drug commercialization processes for academic and industry clients in Taiwan. BioAsia Taiwan will be one of the largest annual biotech events in Asia, BMCC|Drug is delighted to bring these Taiwan Bio-Innotechs to the participants, the professionals from all over the world, to seek collaboration, licensing and investment opportunities.


[Organizer] BioMed Commercialization Center (Drug Division, BMCC|Drug)

[Date] July 25th (Thu), 2019

[Venue] R402a, 4F, Taipei Nangang Exhibition Center, Hall 1 (TNEC1)
(No.1, Jingmao 2nd Rd., Nangang District, Taiepi, Taiwan)

[Registration] Registration is free of charge, however, the organizer reserves the right to change the event program and decide upon admitting the participants.
 
click me to registrate


 

Time

Topic

Presenter

13:00-13:30

Registration

13:30-13:40

Opening Remarks

Chi-Feng Chang,
Vice President,
Development Center for Biotechnology

13:40-13:55

Development of an Autologous Hinge as Universal Ab Lock to Enhance Antibody Drug Selectivity and Safety Humanized
Bispecific Antibodies that Link PEGylated Nanoparticles with
Tumors for Therapy or Imaging

Tian-Lu Cheng,
Professor,
Kaohsiung Medical University

13:55-14:10

Development of WYC-0209-241 as GSTO Inhibitor for Cancer Therapy

Yang-Chang Wu,
Chair Professor,
China Medical University

14:10-14:25

The Novel αIIbβ3 Antagonist TMV-7 and Its Derivative RR Prevent Thrombosis without the Risk of Bleeding

Tur-Fu Huang,
Emeritus Professor,
Mackay Medical College

14:25-14:40

High Yielding CHO Cell Expression System

Hsin-Lin Lu,
Research Fellow,
Development Center for Biotechnology

14:40-14:55

Quantity and Quality Controlled Bioprocess of Chimeric Antigen Receptor (CAR)-T Cells

Hsin-Lin Lu,
Research Fellow,
Development Center for Biotechnology

14:55-15:05

Break

15:05-15:20

Adenosine Augmentation Compounds for the Treatment of Neurodegenerative Diseases

Yijuang Chern,
Distinguished Research Fellow,
Academia Sinica

15:20-15:35

A New Combinational Treatment Method of TMG/DMG with Ketamine for Psychiatric Disorders

Hwei-Hsien Chen,
Investigator,
National Health Research Institutes

15:35-15:50

Highly Selective HDAC6 Inhibitor MPT0G211, in Preclinical Studies, Available for Licensing or Co-development

Shiow-Lin Pan,
Professor,
Taipei Medical University

15:50-16:05

Development of Antibody Drug AP001 against a Novel Tumor Marker Protein AP for Human Cancer Treatment

Wei-Chun HuangFu,
Assistant Professor,
Taipei Medical University

16:05-16:20

Selective Topo-II Chemotherapeutics

Tsai-Kun Li,
Professor,
National Taiwan University

16:20-16:35

Customizable Particles to Enhance the Immunogenicity of Peptide-based T Cell Vaccines

Che-Ming Hu,
Assistant Research Fellow,
Academia Sinica

16:35-16:50 Development of Anti-lung Cancer Peptide Drug Jinghua Tsai Chang,
Assistant Professor,
Chung Shan Medical University

16:50-17:00

Closing